Pro/Con: Should patients taking SGLT2 inhibitors be dropped from the elective surgical program?

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proven to play a key role as pleiotropic drugs beyond treatment of type 2 diabetes mellitus, promoting cardiovascular and renal-protective benefits even in non-diabetic patients. Moreover, SGLT2i have stepped into the spotlight in management of patients with heart failure with a preserved ejection fraction and chronic kidney diseases. Empagliflozin reduced event rates of myocardial infarction, cardiovascular death and strokes in type 2 diabetes mellitus patients compared to placebo, also decreasing hospitalization for cardiac failure [1].
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Pro and Con Source Type: research